The PennZone

  • Home
  • Business
  • Non-profit
  • Construction
  • Real Estate
  • Health
  • Technology
  • Travel
  • Entertainment

YPrime Launches eCOA Gen 5, a Simplified, Protocol-Tailored Solution
The PennZone/10107196

Trending...
  • Still Using Ice? FrostSkin Reinvents Hydration
  • TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
  • Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
MALVERN, Pa.--(BUSINESS WIRE)--YPrime, LLC., a global leader in cloud-based eClinical solutions, announced today the launch of their fifth-generation electronic clinical outcome assessment (eCOA) platform. YPrime's newest platform features an improved user experience for patients, clinical investigators, sponsors, and CROs. This advanced technology enhances clinical trial efficiency, increases site satisfaction, and improves patient compliance. This release also ensures the delivery of cleaner data, streamlining the clinical trial data collection and approval process.

"With a 15-year track record as a technology leader, we are constantly innovating to help drive the digital transformation of clinical research," said YPrime Co-Founder and CEO Shawn Blackburn. "The rapid shift toward a more patient-centered approach to clinical trials is enabled by the strength of our eCOA platform."

More on The PennZone
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • Smallville, Sailor Moon, Reno 911! Stars Added To FAN EXPO Philadelphia Lineup, May 29-31
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)

Tailored for today's complex clinical trials, YPrime's platform helps patients remain engaged and compliant through straightforward design. Developed to integrate intelligently with other eClinical technologies and with the ability to move between devices, YPrime offers a customized solution with the necessary control and security that ensures accurate data collection from specification to submission.

"Real-time data access enhances project control for sponsors and empowers their decision-making," said Michael Hughes, senior vice president, product development. "With superior processing power and advanced security protections, clinical development teams can be assured that they'll receive continuous, high-quality data throughout the duration of the study."

About YPrime

YPrime's cloud-based technology streamlines clinical trial data collection and management. YPrime's eCOA and interactive response technology (IRT) platforms introduce greater speed, precision, and data quality to clinical trials. Our consulting services help clients simplify downstream processes, while moving faster and more efficiently to their next development milestone.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Cold. Clean. Anywhere. Meet FrostSkin
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • Brain Drain Unlimited Strengthens Legal Advocacy with Advanced Training from Villanova University
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Pallet Company Partners with Internet Marketing Company
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Don't Get Burned by High Heater Prices in Philly This Winter!
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies

Popular on PennZone

  • Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation - 178
  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care

Similar on PennZone

  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us